Home > conferences > conferences listings > conference details
Bookmark and Share email this event to a colleage
31 July 2010
life sciences/pharma sector

2nd Annual Drug Development for Neurodegenerative Diseases
Advances in Drug Development for Neurodegenerative Diseases and Expediting Discovery through Novel Compounds and Sound Clinical Trials

Event Date: 18-19 May 2010
Location: Hilton Boston Financial District, Boston MA, USA

key conference topics

  • Regeneration in NDD through Neurogenesis
  • Revolutionizing Drug Discovery & Rehabilitation Medicine by Applying Robotics and Information Technology
  • Neuroimaging Biomarker Developments
  • Hormesis Applications for Neurodegenerative Diseases
  • Allosteric Modulation of Gamma-Secretase Reduces Beta-Amyloid Deposition in a Transgenic Mouse Model of Alzheimer's Disease
  • conference focus

    Continuing its Drug Development for NDD in Pharma series marcus evans invites you to attend the 2nd Annual Drug Development fo

    Continuing its Drug Development for NDD in Pharma series marcus evans invites you to attend the 2nd Annual Drug Development for Neurodegenerative Diseases Conference. More than 18 industry professionals from leading pharmaceutical and biopharma companies will provide valuable insights on innovations within pre-clinical studies, clinical trial designs, biomarker discoveries and target identification for therapeutic and drug discovery journey and will discuss the latest developments in drug discovery for neurodegenerative diseases.

    Hear from your peers first hand on why CNS therapies are helping fuel the rapid advancement of small-molecule drug development. Determine why there is a need to start CNS research and development early with new identifications of several disease-specific genes and proteins, which offer hope for new curative therapies for NDD. The challenges faced in today’s neurodegenerative drug discovery process are big, but significant advances have taken place and the race is on to find the next blockbuster therapy.

    This is not a trade show; our Drug Development for NDD series is targeted at a focused group of 50-60 senior level executives to maintain an intimate atmosphere for the delegates and speakers. Since we are not a vendor driven conference, the higher level focus allows the delegates to network with their industry peers and speakers.

    LinkedIn Group

    Join our Drug Development for Neurodegenerative Diseases LinkedIn Group to be able to start networking with other industry leaders before and after the conference.

    conference sponsors
    Silver Sponsor


    Kinemed

    Silver Sponsor


    Rules Based Medicine

    Prefered Partner


    Goodwyn IRB

    Gold Media Partner


    Future Medicine

    Gold Media Partner


    Future Neurology

    Gold Media Partner


    Karger Medical and Scientific Publishers

    Silver Media Partner


    Alzheimer's Drug Discovery Foundation

    Silver Media Partner


    PharmCast

    Silver Media Partner


    Touch Neurology

    Bronze Media Partner


    Alzheimer Research Forum

    Blog Media Partner


    Life Sciences Blog

    Official Event Blogger


    Prize4Life

    who should attend the conference

    Executives from Pharmaceutical and Biopharma companies, Foundations, Non-profit and Academics with responsibilities or involvement in the following areas:

    CNS Drug Development
    Alzheimer’s Research
    Parkinson’s Research
    Discovery Neurobiology
    Neuroscience Research
    Preclinical Development
    Pharmacogenomics
    Regulatory Affairs
    Translational Medicine
    NDD Clinical Trials

    the conference venue

    Hilton Boston Financial District
    89 Broad Street, Boston MA 02110
    P: 617-556-0006
    http://www1.hilton.com/en_US/hi/hotel/BOSFDHF-Hilton-Boston-Financial-District-Massachusetts/index.do
    Built in 1928 as Boston, Massachusetts' first art deco skyscraper, the historic Hilton Boston Financial District hotel is the ideal blend of old and new. Our stylish renovation brought new luster to our 1920's intimate art deco decor of warm brick, rich woods and brass and added a host of modern comforts and conveniences.

    The hotel's ongoing commitment to superior boutique service and exceptional standards of excellence earned us the coveted AAA Four Diamond Award year after year. Our guests can relax in a spacious guestroom with an enchanting view of the city and enjoy period-style furnishings and thoughtful business amenities like cordless, two-line phones and wireless high-speed Internet access. Savor classic American cuisine at Caliterra Restaurant, relax with a book in the library or unwind in our state-of-the-art fitness facility featuring Precor equipment equipped with individual 12" screen televisions.

    Our team is committed to make your stay a memorable one.The Hilton Boston Financial District hotel is perfectly situated in the heart of downtown Boston, Massachusetts in the Financial District, one block from Boston's Waterfront, ten minutes from Logan International Airport and 1.1 miles from the Boston Convention & Exhibition Center (BCEC). Nearby attractions include Post Office Square, Quincy Market, Faneuil Hall, Downtown Crossing, the Freedom Trail, New England Aquarium, Children's Museum and the TD Banknorth Garden.

    The spacious guest rooms and two-room suites, each with high ceilings and crown molding, make our hotel stand above the other area hotels. Features include such welcome amenities as wireless Internet access, two-line telephones, mini bars, lush bathrobes and 24-hour room service just to name a few.With over 10,000 square feet of flexible meeting and banquet space the historic hotel makes for the perfect location to host your next business or social gathering. The 1,893 square foot Kellogg Ballroom accommodates up to 150 reception guests and divides into three sections. Three well appointed executive boardrooms are available for your next board meeting and 14 additional meeting rooms are ideal for any type of event.

    Meet colleagues in Caliterra's lounge for a casual setting featuring an array of specialty martinis, wines and light fare bar menu, dine in Caliterra Restaurant, our signature restaurant offering a wide variety of culinary cuisine for breakfast, lunch and dinner or enjoy the comfort of our full room service menu. The Hilton Boston Financial District Hotel Features: Gift shop catering to all business and personal needs, Express self check-in kiosk for hotel arrival and airline departures, Experienced full service concierge staff, Wired and wireless Internet access, in all guest rooms, meeting space and public areas, 24-hour executive business center, offering computer, fax, email and copy services, A Professional sales and catering team to assist with all your group & event needs, Hilton HHonors, frequent guest reward program

    the conference organisers

    marcus evans specialises in the research and development of strategic events for senior business executives. From our international network of 63 offices, marcus evans produces over 1000 event days a year on strategic issues in corporate finance, telecommunications, technology, health, transportation, capital markets, human resources and business improvement.

    Above all, marcus evans provides clients with business information and knowledge which enables them to sustain a valuable competitive advantage and makes a positive contribution to their success.



    conference speakers

    Feng Luo M.D., Ph.D.
    Senior Scientist, Translational Neuroimaging, Imaging and Biochemical Biomarkers, Advanced Technology
    Abbott Laboratories

    Roger Lane
    Executive Director, New Products
    Novartis

    Jeff Waring
    Group Leader, Neuroscience Biomarker Discovery
    Abbott Laboratories

    Spyros Papapetropoulos, M.D., Ph.D.
    Associate Medical Director, Neurology/Neurodegenerative Diseases
    Biogen Idec

    Gregory R. Stewart, Ph.D.
    Director, CNS Drug Therapy R&D
    Medtronic Neuromodulation

    Bruce Morimoto
    VP Drug Development
    Allon Pharmaceuticals

    Patrizia Fanara Ph.D.
    Director of Neurodegenerative Diseases
    Kinemed, Inc.

    Cyril De Colle, Ph.D.
    Vice President, Neuroscience
    Kinemed, Inc.

    Robert B. Stein, M.D., Ph.D
    Chief Executive Officer
    Kinemed

    Daniel L. Alkon, M.D.
    BRNI Scientific Director and Toyota Chair
    Blanchette Rockefeller Neuroscience Institute (BRNI)

    C. Anthony Altar
    Director, Alzheimer's Diagnostic Laboratory at Blanchette Rockefeller Neuroscience Institute
    Biotech Blanchette Rockefeller Foundation

    Chengbiao Wu, Ph.D.
    Assistant Professor
    Department of Neurosciences

    Steve Wagner
    Principal Investigator
    UC San Diego Department of Neurosciences

    Edward Calabrese
    Professor of Toxicology
    University of Massachusetts, Amherst

    Anthony Caggiano
    VP Pre-Clinical Development
    Accorda Therapeutics

    Gerhard Koenig
    Chief Scientific Officer
    EnVivo Pharmaceuticals

    Robert Bowser, Ph.D.
    Director, Center for ALS Research
    University of Pittsburgh School of Medicine

    Sid E. O’Bryant, Ph.D.
    Director, Rural Health Research
    F. Marie Hall Institute for Rural & Community Health

    Judith Kelleher-Andersson
    President and Chief Scientific Officer
    Neuronascent, Inc.

    Jeffrey Seeburger, PhD
    Senior Scientist, Clinical Neuroscience
    Merck Research Laboratories

    Michael Palfreyman, PhD, DSc
    Senior Scientific Advisor
    Avineuro Inc.

    general enquiries

    Michele Westergaard

    455 North CityFront Plaza Drive
    9th Floor NBC Tower
    Chicago, IL, 60611

    Telephone:
    312 540 3000 ext 6625
    Fax: 312 552 2155
    Email: michelew@marcusevansch.com


    sponsorship opportunities

    Anthony Knox

    The NBC Tower
    455 North Cityfront Plaza Drive, 9th Floor
    Chicago, IL 60611, USA

    Telephone: 312 540 3000 ext. 6377
    Fax: 312 552 2155
    Email: anthonyk@marcusevansch.com

    conference quote

    "Benchmark with industry peers on the latest developments in drug discovery for neurodegenerative diseases"

    Benchmark with industry peers on the latest developments in drug discovery for neurodegenerative diseases